Effectiveness and safety of SGLT-2 inhibitors for renal allograft recipients with post-transplant diabetes mellitus: an open single-center prospective study
- Authors: Novikova M.S.1, Allazova S.S.2, Molina L.P.1, Koteshkova O.M.1, Antsiferov M.B.1, Kotenko O.N.3,4, Shilov E.M.2
-
Affiliations:
- Dispensary of the Moscow Healthcare Department
- Sechenov University
- City Clinical Hospital № 52 of the Moscow Healthcare Department
- Peoples’ Friendship University of Russia
- Issue: Vol 14, No 2 (2022)
- Pages: 33-41
- Section: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/276127
- DOI: https://doi.org/10.18565/nephrology.2022.233-41
- ID: 276127
Cite item
Abstract
Full Text
About the authors
Maria S. Novikova
Dispensary of the Moscow Healthcare Department
Email: citrus7474@mail.ru
Cand.Sci. (Med.), Nephrologist Moscow, Russia
Sona S. Allazova
Sechenov University
Email: tallisasoto@rambler.ru
Postgraduate Student at the Department of Internal, Occupational Diseases and Rheumatology Moscow, Russia
Lyudmila P. Molina
Dispensary of the Moscow Healthcare DepartmentCand.Sci. (Med.), Cardiologist Moscow, Russia
Olga M. Koteshkova
Dispensary of the Moscow Healthcare DepartmentCand.Sci. (Med.), Endocrinologist Moscow, Russia
Mikhail B. Antsiferov
Dispensary of the Moscow Healthcare Department
Email: ed@zdrav.mos.ru
Dr.Sci. (Med.), Professor, Chief Specialist in Endocrinology of the Moscow Healthcare Department, Chief Physician of the Endocrinological Dispensary of the Moscow Healthcare Department Moscow, Russia
Oleg N. Kotenko
City Clinical Hospital № 52 of the Moscow Healthcare Department; Peoples’ Friendship University of Russia
Email: info@gkb52.mosgorzdrav.ru
Cand.Sci. (Med.), Chief Specialist in Nephrology of the Moscow Healthcare Department, Deputy Chief Physician for Nephrological Care, City Clinical Hospital № 52 of the Moscow Healthcare Department Moscow, Russia
Evgeny M. Shilov
Sechenov University
Email: emshilov@mma.ru
Doctor of Medical Sciences, Professor of the Department of Internal, Occupational Diseases and Rheumatology Moscow, Russia
References
- KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. 2020;98(Suppl. 4). www.kidney-international.org
- Cosio F.G., Kudva Y.,vander Velde M., et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int. 2005;67:2415- 21.
- Chakkera H.A., Weil E.J., Castro J., et al. Hyperglycemia during the immediate period after kidney transplantation. Clin. J. Am. Soc. Nephrol. 2009;4:853-59.
- Hecking M., Haidinger M., D"oller D., et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J. Am. Soc. Nephrol 2012;23:739-49.
- Sharif A., Hecking M., de Vries A.P., et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus:recommendations and future directions. Am. J. Transplant. 2014;14:1992-2000.
- Hjelmesaeth J., Hartmann A., Leivestad T., et al. The impact of early-diagnosed new-onset posttransplantation diabetes mellitus on survival and major cardiac events. Kidney Int. 2006;69:588-95.
- Davies M.J., D’Alessio D.A., Fradkin J., et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diab. Care. 2018;41:2669-701.
- Lopaschuk G., Verma S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC: Basic Translat. Sci. 2020;5(6):632-44.
- Giorgino F., Vora J., Fenici P., Solini A. Cardiovascular protection with sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Does it apply to all patients? Diab. Obes. Metab. 2020;22(9):1481-95. doi: 10.1111/dom.14055. [Published: SEP 2020].
- Fitchett D. A safety update on sodium glucose co-transporter 2 inhibitors. Diab. Obes. Metab. 2019;21(Suppl. 2):34-42. https://doi.org/10.1111/dom.13611
- Ekberg H., Tedesco-Silva H., Demirbas A., et al.; ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N. Engl. J. Med. 2007;357:2562-75.
- Heerspink H.J., Perkins B.A., Fitchett D.H., et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulat. 2016;134:752-72.
- Wanner C., Inzucchi S.E., Lachin J.M., et al.; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 2016;375:323-34.
- American Diabetes Association. Executive summary: standards of medical care in diabetes-2012. Diab. Care. 2012;35(Suppl. 1):S4-10.
- Snow G. Blockrand: randomization for block random clinical trials [Internet], 2013. R package version 1.3. Available from https: CRAN.R-project.org/package=blockrand. Accessed 7 January 2019.
- Хельсинская декларация всемирной медицинской ассоциации. Этические принципы медицинских исследований с участием человека в качестве объекта исследования. http://www.wma.net/en/30publications/10policies/b3/index.html
- Levey A.S., Coresh J., Greene T., et al. Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann.Intern. Med. 2006;145(4):247-54.
- Nagaraja P., Ravindran V., Morris-Stiff G., Baboolal K. Role of insulin resistance indices in predicting new-onset diabetes after kidney transplantation. Transpl.Internat. 2013;26(3):273-80.
- Sharif A., Ravindran V., Moore R.H., et al. Insulin resistance indexes in renal transplant recipients maintained on tacrolimus immunosuppression. Transplantat. 2010;89:327.
- Hjelmesaeth J., Midtvedt K., Jenssen T., Hartmann A. Insulin resistance after renal transplantation: impact of immunosuppressive and antihypertensive therapy. Diab. Care. 2001;24:2121-26.
- Haffner S.M., Miettinen H., Stern M.P., et al. The Homeostasis Model in the San Antonio Heart Study. Diab. Care. 1997;20(7):1087-92. https://doi.org/10.2337/diacare.20.7.1087
- Levey A.S., Inker A.L. Definition and staging of chronic kidney disease in adults [Internet], 2016. Up To Date. Available from https://www.uptodate.com/contents/definition-and-stagingof-chronic-kidney-disease-in-adults#H27258970. Accessed 15 November 2018.
- Van Bommel E.J., Muskiet M.H., Tonneijck L., et al. SGLT2 inhibition in the diabetic kidney-from mechanisms to clinical outcome. Clin. J. Am. Soc. Nephrol. 2017;12:700-10.
- Tikkanen I., Narko K., Zeller C., et al.; EMPAREG BP Investigators. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diab. Care. 2015;38:420-28.
- H"aring H.U., Merker L., Seewaldt-Becker E., et al.; EMPA-REG MET Trial Investigators. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diab. Care. 2014;37:1650-59.
- Fattah H., Vallon V. The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus. Drugs. 2018;78:717-26.
- Kohler S., Salsali A., Hantel S., et al. Safetyand tolerability of empagliflozin in patients with type 2 diabetes. Clin. Ther. 2016;38:1299-313.
- Wiviott S.D., Raz I., Bonaca M.P., et al. DECLARE-TIMI58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 2019;380:347-57.
- Neal B., Perkovic V., Mahaffey K.W., et al.; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type2diabetes. N. Engl. J. Med. 2017;377:644-57.